NasdaqGS - Nasdaq Real Time Price USD
Terns Pharmaceuticals, Inc. (TERN)
2.9000
-0.1200
(-3.97%)
At close: May 13 at 4:00:01 PM EDT
2.8700
-0.03
(-1.03%)
After hours: May 13 at 7:50:15 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 510 | 1 |
| Sales | 37,621 | 4 |
| Net Shares Purchased (Sold) | -37,111 | 5 |
| Total Insider Shares Held | 219.22k | -- |
| % Net Shares Purchased (Sold) | -14.50% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| KURIAKOSE EMIL T. Officer | Sale at price 2.49 per share. | Direct | 2,366 | Apr 1, 2025 |
| VIGNOLA MARK J. Chief Financial Officer | Sale at price 5.72 - 5.80 per share. | Direct | 99,024 | Jan 6, 2025 |
| QUIGLEY JILL M. Director | Sale at price 5.72 - 5.79 per share. | Direct | 86,460 | Jan 6, 2025 |
| KURIAKOSE EMIL T. Officer | Sale at price 5.71 per share. | Direct | 25,607 | Jan 2, 2025 |
| BURROUGHS AMY LOUISE Chief Executive Officer | Purchase at price 5.11 per share. | Direct | 2,606 | Nov 29, 2024 |
| LU HONGBO B Director | Purchase at price 10.50 per share. | Indirect | 4,999,995 | Sep 12, 2024 |
| VIGNOLA MARK J. Chief Financial Officer | Conversion of Exercise of derivative security at price 5.36 per share. | Direct | 53,600 | Sep 10, 2024 |
| VIGNOLA MARK J. Chief Financial Officer | Sale at price 11.00 per share. | Direct | 110,000 | Sep 10, 2024 |
| QUIGLEY JILL M. Director | Conversion of Exercise of derivative security at price 1.82 per share. | Direct | 31,368 | Sep 9, 2024 |
| QUIGLEY JILL M. Director | Sale at price 10.00 per share. | Direct | 172,350 | Sep 9, 2024 |
| QUIGLEY JILL M. Director | Sale at price 7.50 - 7.68 per share. | Direct | 113,580 | Aug 2, 2024 |
| QUIGLEY JILL M. Director | Conversion of Exercise of derivative security at price 1.82 per share. | Direct | 26,872 | Jul 16, 2024 |
| GORDON CARL L Director and Beneficial Owner of more than 10% of a Class of Security | Sale at price 10.00 per share. | Indirect | 561,640 | Jul 16, 2024 |
| ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security | Sale at price 10.00 per share. | Indirect | 561,640 | Jul 16, 2024 |
| QUIGLEY JILL M. Director | Sale at price 10.00 per share. | Direct | 147,660 | Jul 16, 2024 |
| YOON SEOKHO BRYAN Chief Operating Officer | Purchase at price 6.01 per share. | Direct | 28,794 | May 31, 2024 |
| VIVO OPPORTUNITY LLC Beneficial Owner of more than 10% of a Class of Security | Sale at price 6.20 - 6.99 per share. | Indirect | 2,796,859 | Apr 3, 2024 |
| YOON SEOKHO BRYAN Chief Operating Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 23, 2024 |
| VIGNOLA MARK J. Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 23, 2024 |
| QUIGLEY JILL M. Officer and Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 23, 2024 |
| QUIRK ERIN M.D. Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 23, 2024 |
| YOON SEOKHO BRYAN Chief Operating Officer | Purchase at price 3.78 per share. | Direct | 2,809 | Nov 30, 2023 |
| QUIGLEY JILL M. Officer and Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Nov 15, 2023 |
| SUNDARAM SENTHIL VEL Chief Executive Officer | Purchase at price 10.61 per share. | Direct | 22,398 | May 31, 2023 |
| YOON SEOKHO BRYAN Chief Operating Officer | Purchase at price 10.61 per share. | Direct | 106,068 | May 31, 2023 |
Related Tickers
GPCR Structure Therapeutics Inc.
23.89
-2.97%
DAWN Day One Biopharmaceuticals, Inc.
6.33
-3.80%
ALT Altimmune, Inc.
5.76
-4.16%
ATYR aTyr Pharma, Inc.
3.3100
+2.16%
AKRO Akero Therapeutics, Inc.
40.01
-3.66%
MDGL Madrigal Pharmaceuticals, Inc.
295.36
-1.80%
VKTX Viking Therapeutics, Inc.
27.74
-2.00%
CRVS Corvus Pharmaceuticals, Inc.
3.8900
-4.07%
PRTA Prothena Corporation plc
7.59
-0.26%
VNDA Vanda Pharmaceuticals Inc.
3.9800
-1.24%